Статья
Системные факторы риска окклюзии вен сетчатки у лиц молодого и среднего возраста
Окклюзия вен сетчатки (ОВС) — острое сосудистое заболевание сетчатки, ассоциированное с локальным и общим нарушением функции эндотелия сосудов. В обзоре рассмотрены возможные причины развития заболевания у лиц молодого и среднего возраста, на долю которых приходится около 25 % всех случаев ОВС. Большое внимание уделено таким независимым факторам риска развития ОВС, как артериальная гипертензия (в том числе «маскированная»), дислипидемия, сахарный диабет и наследственные и приобретенные нарушения системы гемостаза. Подчеркнута необходимость мультидисциплинарного подхода к ведению пациентов с венозной ретинальной окклюзией.
1. Rogers S, McIntosh R, Cheung N, Lim L, Wang JJ, Mitchell P et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313–319. doi:10.1016/j. ophtha.2009.07.017
2. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886– 1894.
3. Koizumi H, Ferrara DC, Brue C, Spaide RF. Central vein occlusion case-control study. Am J Ophthalm. 2007; 144(6): 858–863.
4. Тульцева С. Н. Роль наследственных и приобретенных факторов тромбофилии в патогенезе окклюзий вен сетчатки: автореферат диссертации на соискание ученой степени доктора медицинских наук. Санкт-Петербург: ФГБУ ВПО ПСПбГМУ им. акад. И. П. Павлова; 2014..
5. O’Mahoney P, Wong D, Ray J. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126(5):692–699.
6. Shahsuvaryan M, Melkonyan A. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol. 2003;13(5):445–452.
7. Hayerh S, Zimmerman B, McCarthy M, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131(1):62–77.
8. Stem M, Talwar N, Comer G, Stein J. A longitudinal analysis of risk factors associated with central retinal vein occlusion. Am J Ophthalmol. 2013;120(2):362–370. doi:0.1016/j.ophtha.2012. 07.080
9. Aghamirsalim M, Sorbi R, Naderian M, Cugati S, Shahsuvaryan M, Hashemi M. Management of retinal vein occlusion, who is responsible? Acta Med Iran. 2016;54(11):731–736.
10. Janssen M, den Heijer M, Cruysberg J, Wollersheim H, Bredie S. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? J Thromb Haemost. 2005;93:1021– 1026.
11. Shin Y, Cho H, Kim J, Bae K, Kang M, Shin J et al. Prevalence and associated factors of retinal vein occlusion in the Korean National Health and Nutritional Examination Survey, 2008–2012. Medicine. 2016;95(44):1–8.
12. Ponto K, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild P et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost. 2015;13(7):1254– 1263. doi:10.1111/jth.12982
13. Rosa A, Ortega K, Decio Mion J, Nakashima Y. Prevalence of arterial hypertension in branch retinal vein occlusion patients. Arg Bras Oftalmol. 2008;71(2):162–166.
14. Zhou J, Xu L, Wang S, Wang YX, You QS, Tu Y et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology. 2013;120(4):803–808. doi:10.1016/ j.ophtha.2012.09.033
15. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol So. 2000;98:133–143.
16. Yau J, Lee P, Wong T, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38(12):904–910. doi:10.1111/ j.1445-5994.2008.01720.x
17. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014;2014:1–5. doi:10.1155/2014/724780
18. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation. 2014;129 (3):28–292. doi: 10.1161/01.cir.0000441139.02102.80
19. Drukteinis J, Roman M, Fabsitz R, Lee ET, Best LG, Russell M et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: The Strong Heart Study. Circulation 2006;115(2): 221–227
20. Recchia F, Carvalho-Recchia C, Hassan T. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol. 2004;122(3):317–321.
21. Balogh Z, Berta A, Pfliegler G, Nagy V. Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient. Clin Exp Hypertens. 2011;33(1):53–55.
22. Ahluwalia J, Rao S, Varma S, Gupta A, Bose S, Masih J et al. Thrombophilic risk factors are uncommon in young patients with retinal vein occlusion. Retina. 2015;35(4):715–719. doi:10.1097/ IAE.0000000000000366
23. Lam H, Lahey J, Kearney J, Od R, Lehmer J, Tanaka S. Young patients with branch retinal vein occlusion. Retina. 2010;30 (9):1520–1523.
24. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993;37(6):393–417
25. Liu Q, Lahey M, Karlen R, Stewart J. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Retina. 2018;38(6):1175–1179. doi:10.1097/IAE.0000000000001661
26. Kuhli-Hattenbach C, Scharrer I, Luchtenberg M, Hattenbach L. Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost. 2010;103(2):299–305.
27. Glueck CJ, Hutchins RK, Jurantee J, Khan Z, Wang P. Thrombophilia and retinal vascular occlusion. Clin Ophthalmol. 2012;6:1377–1384. doi:10.2147/OPTH.S34627
28. Rehak M, Rehak J, Muller M, Faude S, Faude F, Siegemund A et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Thromb Haemost. 2008;99(5):925–929. doi:10.1160/TH07-11-0658
29. Wittstrom E. Central retina vein occlusion in younger Swedish adults: case reports and review of the literature. Open Ophthalmol J. 2017;11:89–102. doi:10.2174/1874364101711010089
30. Hayreh S, Zimmerman M. Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmology. 2014;132 (1):13–22.
31. Hayreh S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Progr Retinal Eye Res. 2005;24 (4):493–519.
32. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006;12(13):1581–1592.
33. Rubattu S, Pagliaro B, Pierelli G, Santolamazza C, Castro SD, Mennuni S et al. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2014;16(1):823–839. doi:10.3390/ijms16010823
34. Schulz E, Wenzel P, Münzel T, Daiber A. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal. 2014;20(2):308–324.
35. Redheuil A, Yu WC, Wu CO, Mousseaux E, de Cesare A, Yan R et al. Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension. 2010;55 (2):319–326. doi:10.1161/HYPERTENSIONAHA.109.141275
36. O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007; 50(1):1–13.
37. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105 (3):424–427.
38. Christoffersen NLB, Larsen M. Pathophysiology and hemodynamics of BRVO. Ophthalmology. 1999;106(11):2054–62.
39. Kida T, Flammer J, Oku H, Konieczka K, Morishita S, Horie T, Ikeda T. Vasoactivity of retinal veins: a potential involvement of endothelin-1 (ET-1) in the pathogenesis of retinal vein occlusion (RVO). Exp Eye Res. 2018;176:207–209. doi:10.1016/j.exer.2018. 07.016
40. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Tenyear incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124 (5):726–32
41. Di Capua M, Coppola A, Albisinni R, Tufano A, Guida A et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis. 2010;30(1):16–22. doi: 10.1007/s11239-009-0388-1.1
42. Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol. 2009;147(2):283–90. doi:10.1016/j.ajo.2008.08.006
43. Rothman A, Thomas A, Khan K, Fekrat S. Central retinal vein occlusion in young individuals. Retina. 2018;1–8. doi:10. 1097/IAE.0000000000002278
44. Лямина Н. П., Наливаева А. В., Сенчихин В. Н., Липчанская Т. П. Маскированная артериальная гипертензия у лиц молодого возраста: встречаемость, выраженность кардиоваскулярных факторов риска и прогноз с учетом гендерных различий. Российский кардиологический журнал. 2017; (4):7–12..
45. Rao V, Ulrich N, Viera A, Parlin A, Fekrat S, Chavala S. Ambulatory blood pressure patterns in patients with retinal vein occlusion. Retina. 2016;36(12):2304–2310.
46. Тульцева С. Н., Астахов Ю. С., Титаренко А. И., Руховец А. Г. Суточный профиль артериального давления у пациентов с окклюзией вен сетчатки молодого и среднего возраста. Артериальная гипертензия. 2017;23(2):122–130..
47. Park S, Moon S, Lim S, Yoon I, Choi K, Lee H. Diurnal blood pressure variation in the retinal vein occlusion. J Korean Ophthalmol Soc. 2013;54(9):1371–1378.
48. Pesin N, Mandelcorn E, Felfeli T, Ogilvie R, Brent M. The role of occult hypertension in retinal vein occlusions and diabetic retinopathy. Can Ophthalmol Soc. 2017;52(1):31–33.
49. Tanano I, Nagaoka T, Sogawa K, Tani T, Omae T, Nakabayashi S et al. Impaired systemic vascular endothelial function in patients with branch retinal vein occlusion. Curr Eye Res. 2013;38(1):114–118. doi:10.3109/02713683.2012.738460
50. Hollo G. Plasma endothelial-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1999;83(1):127– 128.
51. Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. EPMA J. 2015;6:1–12. doi:10.1186/s13167015-0043-1
52. Martinez F, Furio E, Fabia M, Perez A, GonzalezAlbert V, Rojo-Martinez G et al. Risk factors associated with retinal vein occlusion. Int J Clin Pract. 2014;68(7):871–881. doi:10. 1111/ijcp.12390
53. Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol. 2004;122(3):317–321.
54. Kuo J, Lai C, Ong F, Shih C, Yeung L, Chen U et al. Central retinal vein occlusion in a young Chinese population. Retina. 2010;30(3):479–484. doi:10.1097/IAE.0b013e3181b9b3a0
55. Kuhli-Hattenbach C, Miesbach W, Luchtenberg M, Kohnen T, Hattenbach L. Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion. Acta Ophthalmica. 2017;95 (2):140–145. doi:10.111/aos.13228
56. Тульцева С. Н. Тромбофилия как фактор риска развития тромбозов центральной вены сетчатки у лиц молодого возраста. Офтальмологические ведомости. 2008;1(1):46–51..
57. Rehak M, Krcova V, Slavik L, Fric E, Langova K, Ulehlova J et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol. 2010;45 (2):171–175.
58. Karska-Basta I, Kubicka-Trzaska A. Thrombophilia — a risk factor of retinal vein occlusion? Klin Oczna. 2013;115 (1):29–33
59. Glueck CJ, Wang P, Hutchins R, Petersen MR, Golnik K. Ocular vascular thrombotic events: central retinal vein and central retinal artery occlusions. Clin Applied Thromb Hemost. 2008;14 (3):286–294.
60. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002; 240(3):163–168.
61. Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol. 2017;11:441–447. doi:10.2147/OPTH.S128341
62. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitaminB12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136(6):1136–1150.
63. Gopinath B, Wang JJ, Flood VM, Burlutsky G, Wong TY, Mitchell P. The associations between blood levels of homocysteine, folate, vitamin B12, and retinal vascular caliber. Am J Ophthalmol. 2009;148(6):902–909. doi:10.1016/j.ajo.2009.07.018
64. Narayanasamy A, Subramaniam B, Karunakaran C, Ranganathan P, Sivaramakrishnan R, Sharma T et al. Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusions in an Indian population. Invest Ophthalmol Vis Sci. 2007;48(4):1441–1446.
65. Li D, Zhou M, Peng X, Sun H. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis. BMC Ophthalmology. 2014;14:1471–1447. doi:10.1186/1471-241514-147
66. Sottilotta G, Siboni SM, Latella C, Oriana V, Romeo E, Santoro R et al. Hyperhomocystinemia and C677T MTHFR genotype in patients with retinal vein thrombosis. Clin Appl Thromb Hemost. 2010;16(5):549–553. doi:10.1177/1076029609348644
67. Devi S, Suganeswari G, Sharma T, Thennarasu M, Anayarkanni N. Homocysteine induces oxidative stress in young adult central retinal vein occlusion. Br J Ophthalmol. 2012;96:1122–1126. doi:10.1136/bjophthalmol-2011-301370
68. Wadani F, Khandekar R, Salim G, Ali M, Ramzi S. Hyperhomocysteinia is a risk for retinal venous occlusion: A case control study. 2014;62(3):291–294. doi:10/4103/03014738. 111213
69. Salaun N, Delyfer MN, Rougier MB, Korobelnik JF. Assessment of risk factors for retinal vein occlusions in patients under 60 years of age. J Fr Ophthalmol. 2017;30(9):918–923.
70. Napal J, Neila S, Perez-Montes R, Sierra I, Ruiz S, Hernandez J. The role of coagulation disorders in patients with retinal vein occlusion. QJM. 2016;109(2):97–102. doi:10.1093/ qjmed/hcv088
71. Sartori M, Barbar S, Dona A, Piermarocchi S, Pilotto E, Saggiorato G et al. Risk factors antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study. Eur J Haematol. 2013;90(5):426–33. doi:10.1111/ ejh.12099
72. Sottilotta G, Orina V, Latella C, Luise F, Piromalli A, Ramirez F et al. Role of hyperhomocystinemia in retinal vascular occlusive disease. Clin Appl Thromb Hemost. 2007;13(1):104– 107.
73. Sofi F, Rossella M, Bolli P, Giambene B, Sodi A, Fedi S et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis. 2008;198(1):223–227.
74. Vine AK. Investigation of patients with retinal arterial or venous occlusive disease. Compr Ophthalmol Update. 2003; 4:193–199.
75. Bashshur Z, Taher A, Masri A, Najjar D, Arayssi T, Noureddin B. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors. Retina. 2003;23(4):486–490.
76. Carbone J, Sanchez-Ramon S, Cobo-Soriano R, Seoane E, Aparicio MJ, Ruiz-Tiscar JL. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with inflammatory diseases. J Rheumatol. 2001;28(11):2437– 2441.
77. Werther W, Chu L, Holekamp N, Do D, Rubio R. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;122(3):326–331.
78. Li M, Xiaolan H, Huang J, Tan Y, Yang B, Tang Z. Impact of retinal vein occlusion on stroke incidence: a meta-analysis. J Am Heart Assoc. 2016;5(12): pii: e004703. doi:10.1161/JAHA.116.004703